Clinical Trial Update: Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions [Phase 2]

View source ↗

Summary

Phase 2 study evaluating baricitinib for moderate to severe traumatic intracerebral hemorrhage/contusions is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Traumatic Brain Injury | Phase 2 | Status: RECRUITING